Adrenergic beta-Antagonists
"Adrenergic beta-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
| Descriptor ID |
D000319
|
| MeSH Number(s) |
D27.505.519.625.050.200.200 D27.505.696.577.050.200.200
|
| Concept/Terms |
Adrenergic beta-Antagonists- Adrenergic beta-Antagonists
- Adrenergic beta Antagonists
- beta-Antagonists, Adrenergic
- beta-Adrenergic Receptor Blockaders
- Blockaders, beta-Adrenergic Receptor
- Receptor Blockaders, beta-Adrenergic
- beta Adrenergic Receptor Blockaders
- beta-Adrenergic Blockers
- Blockers, beta-Adrenergic
- beta Adrenergic Blockers
- beta-Blockers, Adrenergic
- Adrenergic beta-Blockers
- beta Blockers, Adrenergic
- Adrenergic beta-Receptor Blockaders
- Adrenergic beta Receptor Blockaders
- Blockaders, Adrenergic beta-Receptor
- beta-Receptor Blockaders, Adrenergic
- beta-Adrenergic Blocking Agents
- Agents, beta-Adrenergic Blocking
- Blocking Agents, beta-Adrenergic
- beta Adrenergic Blocking Agents
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-Antagonists".
This graph shows the total number of publications written about "Adrenergic beta-Antagonists" by people in this website by year, and whether "Adrenergic beta-Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 5 | 2 | 7 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 4 | 4 |
| 2002 | 3 | 3 | 6 |
| 2003 | 4 | 3 | 7 |
| 2004 | 2 | 2 | 4 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 4 | 5 |
| 2007 | 7 | 4 | 11 |
| 2008 | 4 | 5 | 9 |
| 2009 | 2 | 5 | 7 |
| 2010 | 3 | 4 | 7 |
| 2011 | 2 | 5 | 7 |
| 2012 | 3 | 2 | 5 |
| 2013 | 3 | 4 | 7 |
| 2014 | 8 | 4 | 12 |
| 2015 | 4 | 4 | 8 |
| 2016 | 5 | 4 | 9 |
| 2017 | 4 | 2 | 6 |
| 2018 | 5 | 2 | 7 |
| 2019 | 5 | 4 | 9 |
| 2020 | 4 | 3 | 7 |
| 2021 | 6 | 2 | 8 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 4 | 4 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic beta-Antagonists" by people in Profiles.
-
Prevention of heart failure after acute myocardial infarction. Lancet. 2025 Sep 13; 406(10508):1154-1170.
-
Utility of Cardiopulmonary Exercise Testing in Assessing Beta-Blocker Efficacy in LQTS: Moving Away From One-Size-Fits-All. J Cardiovasc Electrophysiol. 2025 Sep; 36(9):2287-2295.
-
Exercise-induced ?2-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells. Brain Behav Immun. 2025 Aug; 128:751-765.
-
Pharmacogenetic and microRNA mechanisms of beta blocker use on bone. J Bone Miner Res. 2025 Feb 02; 40(2):231-240.
-
Use of Early Intravenous Beta Blockers in Patients with Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure-Revival or Requiem? Cardiovasc Drugs Ther. 2024 Oct; 38(5):973-975.
-
Protective Effects of ?-Blockers on Bone in Older Adults with Dementia. Calcif Tissue Int. 2024 Jul; 115(1):14-22.
-
Factors associated with longer survival among older medicare patients after diagnosis of supratentorial primary brain malignancies: a retrospective cohort study. Neurol Res. 2024 May; 46(5):379-390.
-
How do we define high and low dose intensity of heart failure medications: a scoping review. BMC Cardiovasc Disord. 2023 09 27; 23(1):478.
-
Practice Variations in Managing Infantile Hemangiomas. J Pediatr Hematol Oncol. 2023 11 01; 45(8):452-460.
-
Mortality, Outcomes, Costs, and Use of?Medicines Following a First Heart?Failure?Hospitalization: EVOLUTION HF. JACC Heart Fail. 2023 10; 11(10):1320-1332.